| Title | EXP | AOP Code | Reward  |
Winning Advisors |
|---|---|---|---|---|
TECHNOLOGY - SOFTWARESPEECH RECOGNITION PATENTSCONGRATULATIONS TO OUR THREE WINNERS! Article One Partners, the world's largest patent validation firm, congratulates our latest winners - Engr009, Ramesh, and Lankesh. |
07/12/10 | DSI 279 | $5,000 |
Ramesh Engr009 Lankesh |
TECHNOLOGY - SOFTWARECONTEXT ORIENTED CRYPTO PROCESSING ON A PARALLEL PROCESSOR ARRAYCONGRATULATIONS, MAGNUM! Article One Partners, the world's largest patent validation firm, congratulates our latest winner Magnum. |
06/28/10 | TSI 448 | $10,000 |
Magnum |
TECHNOLOGY - SOFTWARESYSTEM AND METHOD FOR DEVELOPING RULES UTILIZED IN A KNOWLEDGE MANAGEMENT SYSTEMCLOSED |
06/14/10 | WTL 133 | $10,000 |
Fuzon |
TECHNOLOGY - SOFTWAREFACEBOOK DEFENSE - MANAGING ONLINE NETWORK MEMBER RELATIONSHIPSWINNING PRIOR ART FOUND THAT CAN SHOW THE WHOGLUE PATENT TO BE INVALID Article One Partners, the world's largest patent validation firm, congratulates our latest winner! Advisor Specialist submitted prior art that can show the WhoGlue U.S. patent to be invalid. |
01/04/10 | WG 164 | $20,000 |
Specialist |
TECHNOLOGY - SOFTWAREWIRELESS COMMUNICATIONS AND CALL SIGNALS VIA MOBILE DEVICE (SMS AND MMS)CONGRATULATIONS TO THE AOP COMMUNITY FOR A SUCCESS IN THIS STUDY! THE REWARD HAS BEEN EARNED BY THE ADVISOR WHO PROVIDED A NEW PATH TO INVALIDITY. Article One Partners, the world's largest patent validation firm, announces the conclusion of this Study as a success for the AOP community! The community has identified evidence forming a new path to invalidity for the subject patents. |
05/10/10 | HPL 956 | $15,000 |
Magnum |
TECHNOLOGY - SOFTWARECONTENT PROVIDER SYSTEMS AND SERVICES TO MOBILE DEVICESCONGRATULATIONS TO THE AOP COMMUNITY FOR A SUCCESS IN THIS STUDY! THE REWARD HAS BEEN EARNED BY THE ADVISORS WHO PROVIDED A NEW PATH TO INVALIDITY.
|
05/09/10 | HPL 241 | $10,000 |
Magnum Irfan |
TECHNOLOGY - SOFTWAREDEVICES, MECHANISMS AND METHODS FOR PLAYING AND STORING SEGMENTED CONTINUOUS PLAY MEDIA STREAMSWINNING PRIOR ART FOUND THAT CAN SHOW THE MONKEY MEDIA PATENTS TO BE INVALID Article One Partners, the world's largest patent validation firm, congratulates our latest winner! Advisor one1337 submitted prior art that can show the Monkey Media U.S. patents to be invalid. |
04/30/10 | MM 158 | $10,000 |
one1337 |
TECHNOLOGY - SOFTWAREXML ENCRYPTION SCHEMECONGRATULATIONS, PRIORARTISAN! Article One Partners, the world's largest patent validation firm, congratulates our latest winner PriorArtisan. |
06/28/10 | TSI 433 | $10,000 |
priorArtisan |
TECHNOLOGY - SOFTWAREDISTRIBUTED CRYPTOGRAPHIC OBJECT METHODCONGRATULATIONS TO OUR THREE WINNERS! Article One Partners, the world's largest patent validation firm, congratulates our latest winners - jsmorph, Magnum, and EagleEye. |
06/28/10 | TSI 702 | $10,000 |
EagleEye Magnum jsmorph |
TECHNOLOGY - SOFTWAREMODULAR AND CUSTOMIZABLE PROCESS AND SYSTEM FOR CAPTURING FIELD DOCUMENTATION DATA IN A COMPLEX PROJECT WORKFLOW SYSTEMCLOSED |
06/14/10 | WTL 486 | $10,000 |
msasangu |
TECHNOLOGY - SOFTWAREAUDITING TRANSACTIONS BASED ON BIOMETRIC READINGSCLOSED |
08/09/10 | AETB 545 | $5,000 |
yoovee |
TECHNOLOGY - AUTOMOTIVEMETHOD FOR STOPPING AND STARTING AN ENGINECONGRATULATIONS TO ADVISOR RISKMENTOR FOR IDENTIFYING THE HIGHEST QUALITY ART EVIDENCE FOR THIS GUARANTEED REWARD PAYMENT.
|
01/30/10 | AUTO 442 | $15,000 |
Riskmentor |
TECHNOLOGY - AUTOMOTIVEAUTOMOBILE WITH STOP/START SYSTEMCONGRATULATIONS TO ADVISOR PRIORARTISAN FOR IDENTIFYING THE HIGHEST QUALITY ART EVIDENCE FOR THIS GUARANTEED REWARD PAYMENT. Article One Partners, the world's largest patent validation firm, announces the conclusion of its State of the Art collection Studies conducted on behalf of a worldwide automaker. |
01/30/10 | AUTO 655 | $15,000 |
PriorArtisan |
TECHNOLOGY - WIRELESS COMMUNICATIONCOHERENT DUAL-CHANNEL QPSK MODULATOR/DEMODULATOR FOR CDMA SYSTEMS, AND MODULATING/DEMODULATING METHODS THEREFORWINNING PRIOR ART FOUND THAT CAN SHOW THE ETRI PATENT TO BE INVALID |
05/05/10 | ETRI 029 | $10,000 |
Kepler |
HEALTHCARE - MEDICAL & SURGICAL DEVICESNEGATIVE PRESSURE WOUND THERAPYClosed -
invalid due to known prior art. |
01/15/10 | MED 081 | $25,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - TELEPHONE APPARATUSSPEECH PROCESSING - RIMMClosed - invalid due to known prior art. |
09/30/09 | RIMM 055 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALGEODON - PFIZERArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
11/02/09 | PFE 031 | $20,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALXELODA - ROCHEWINNING PRIOR ART FOUND FOR 2 SEPARATE PATHS THAT CAN SHOW THE XELODA PATENT TO BE INVALID! Article One congratulates our latest winners! Advisors Anonymous and Magnum submitted prior art that can show that the U.S. patent for XELODA is invalid as verified by an independent law firm. The winning references disclose the substitution used to construct the N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine molecule as well as support for why the substitution would be made. Anonymous and Magnum will share the $25,000 Reward for this Study, demonstrating why they belong in the ranks of our Genius Advisors.
|
08/15/09 | RHHBY 949 | $25,000 |
Magnum Anonymous |
HEALTHCARE - PHARMACEUTICALHORMONAL CONTRACEPTIONWINNING PRIOR ART FOUND THAT CAN SHOW THE WYETH HORMONAL CONTRACEPTIVE PATENT TO BE INVALID! |
08/15/09 | WYE 814 | $15,000 |
DDenim Chargerpeet |
TECHNOLOGY - WIRELESS COMMUNICATIONEMER 911 LOCATION DETECTION FOR MOBILE PHONESWINNING PRIOR ART FOUND THAT CAN SHOW THE EMSAT PATENTS TO BE INVALID! Article One congratulates our latest winners! Advisors Skrib1, Clause8 and Anonymous submitted prior art that can show the EMSAT U.S. patents for Location detection for mobile phones to be invalid. The winning submissions disclose each of the claimed elements and teach why a person of ordinary skill in the art at the time of the invention would have been motivated to combine all of the claimed elements. EMSAT Advanced Geo-Location Technology asserted industry-wide patent infringement litigation in Federal Court, accusing 20 defendants, including Sprint, MetroPCS, T-Mobile and Verizon. The litigations focus upon infringement of four patents which potentially cover mobile phone services related to location services provided to the Emergency 911 system, used in implementing Phase II services of the E-911 service. |
04/15/09 | EMER 911 | $50,000 |
Skrib1 Anonymous Clause8 |
TECHNOLOGY - TELEPHONE APPARATUSCELLPHONES - MINERVAWINNING STUDY, TWO SEPARATE PATHS TO INVALIDITY IDENTIFIED FOR DEFENSE AGAINST MINERVA INDUSTRIES' PATENT INFRINGEMENT LITIGATION! Article One is excited to announce our community's newest set of winning Advisors - Columbo, Singh and Ramesh - for their success in identifying two independent paths to invalidity. The Minerva Study uncovered new dramatic invalidating prior art that extensive traditional prior art searches didn’t produce AOP’s evidence has not been introduced in pending reexaminations. With so many Article One Advisors using different approaches, unique references unlikely to be found through traditional searching were uncovered. The references include foreign patents, detailed product announcements, product brochures and web pages. The proprietary collection is available for license. |
01/29/09 | Min 120 | $50,000 |
Singh Ramesh Columbo |
HEALTHCARE - PHARMACEUTICALLEVITRA - BAYERArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
11/02/09 | BAYRY-178 | $15,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALDORYX - WARNER CHILCOTT, MAYNEArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
08/15/09 | WCRX 161 | $15,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - HOUSEHOLD AUDIO/VIDEOBLU-RAY DISC DRIVES TECHNOLOGYArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
03/31/09 | SONY 560 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - MEDICAL DIAGNOSTICSSEQUENOM'S INFECTIOUS AGENT IDENTIFICATIONArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
06/15/09 | SQNM 076 | $25,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALCYMBALTA/ELI LILLYWINNING PRIOR ART FOUND THAT CAN SHOW THE CYMBALTA PATENT TO BE INVALID! Article One congratulates our latest winner! Advisor Columbo submitted prior art that can show that the U.S. patent for CYMBALTA is invalid as verified by an independent law firm. His winning references disclose the substitutions used to construct the duloxetine molecule as well as support for why the substitutions would be made. Columbo will receive the $50,000 Reward for this Study, demonstrating why he is one of our Genius Advisors. Eli Lilly has sued 8 companies for patent infringement to prevent them from selling a generic version of duloxetine hydrochloride (Cymbalta®). The Article One community uncovered references that teach the claim elements, why the lead molecule would be selected, what results could be expected from substitutions to the lead molecule, and why a person of ordinary skill in the art at that time would have been motivated to make that change. The proprietary collection is available for license. |
03/31/09 | LLY 269 | $50,000 |
Columbo |
TECHNOLOGY - SOFTWAREMUSIC VIDEO GAMES - ACTIVISIONArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | ACTI 457 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - SOFTWAREMUSIC VIDEO GAMES - KONAMIArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | KNM 822 | $50,000 |
PRIOR ART Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALXYZAL/SEPRACORArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
03/31/09 | SEPR 558 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - MEDICAL & SURGICAL DEVICESINTRAVASCULAR STENT - MEDTRONICArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | MDT 650 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALNAMENDA - FOREST LABSArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | FRX 703 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALAMBIEN CR/ SANOFI-AVENTISArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
06/15/09 | SNY 531 | $25,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALLUNESTA/ SEPRACORArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
06/15/09 | SEPR 926 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALCRESTOR - ASTRAZENECAWINNING PRIOR ART FOUND THAT CAN SHOW THE CRESTOR PATENT TO BE INVALID! Article One congratulates our latest winner! Advisor Columbo submitted prior art that can show that the US patent for Crestor is invalid as verified by an independent law firm, Darby and Darby, and an independent expert in medicinal chemistry. Columbo will receive a monetary award and join the ranks of our Genius Advisors. AstraZeneca has sued 9 companies for patent infringement to prevent them from selling a generic version of rosuvastatin calcium (Crestor®). The Article One community uncovered references that teach the claim elements, why the lead molecule would be selected, what results could be expected from substitutions to the lead molecule, and why a person of ordinary skill in the art at that time would have been motivated to make that change. |
03/31/09 | AZN 314 | $50,000 |
Columbo |
TECHNOLOGY - SOFTWARENETWORK-ACCESSIBLE ACCOUNT SYSTEMWINNING STUDY, TWO SEPARATE 102 PRIOR ART REFERENCES IDENTIFIED FOR DEFENSE AGAINST JSA TECHNOLOGY'S PATENT INFRINGEMENT LITIGATION! Article One is delighted to announce our community's newest set of winning Advisors -- Ramesh and Patented - for their success in identifying two independent paths to invalidity under the strongest level of invalidity evidence under "102 anticipation." Article One already has begun to license the proprietary collection, with law firm Davis Wright Tremaine, LLP first to license. The JSA Study uncovered new dramatic invalidating prior art that extensive traditional prior art searches didn’t produce. With so many Article One Advisors using different approaches, a wide variety of highest quality references were found, including two separate 102 invalidity references -- a U.S. patent, and obscure publications about a product offered in 1997. The proprietary collection is available for license to the community. |
03/15/09 | JSA 857 | $50,000 |
Patented Ramesh |
HEALTHCARE - PHARMACEUTICALACTOPLUS MET - TAKEDAArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | TKPHF 584 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALLOTREL - NOVARTISArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | NVS 802 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALOPANA ER/PENWESTArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
03/31/09 | PPCO 933 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALPREVACID - TAKEDAArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | TKPHF 632 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALEFFEXOR XR - WYETHArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | WYE 171 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - WIRELESS COMMUNICATIONWIRELESS TRANSMISSIONS - WI-LANArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes highly relevant references and is available for license. |
01/29/09 | WIN 222 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALLIPITOR - PFIZERArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
01/29/09 | PFE 995 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - SOFTWARESYSTEM AND METHOD FOR ENABLING USERS TO INTERACT IN A VIRTUAL SPACEWINNING PRIOR ART FOUND THAT CAN SHOW THE WORLDS.COM PATENT TO BE INVALID! Article One uncovered prior art including a primary reference for the independent claims and additional references for selected dependent claims. |
03/15/09 | Worlds 690 | $50,000 |
Anonymous |
TECHNOLOGY - WIRELESS COMMUNICATIONKEYBOARD - RIMMArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes highly relevant references and is available for license. |
01/29/09 | RIMM 442 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - MEDICAL & SURGICAL DEVICESANGIOPLASTY STENT - WALLArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes highly relevant references and is available for license. |
01/29/09 | Wall 475 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - TELEPHONE APPARATUSIPHONE'S MULTI-TOUCH TECHNOLOGY - APPLEThe Article One community uncovered the highest quality state of the art collection for Apple's multi-touch screen technology. The art is relevant to U.S. Patent No. 7,479,949 to show the state of the art from before the earliest invention date as well as through the filing date of the patent. Article One offers the prior art collection for the Apple 949 Patent Study for license to the industry. The prior art uncovered by the AOP community is fundamental information to allow members of industry to assess their freedom to operate, and evaluate potential licensing opportunities or acquisitions of patents in multi-touch screen technology for defensive purposes. |
03/31/09 | APPL 949 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - SOFTWARESECURITY FOR FINANCIAL TRANSACTIONSArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license. |
06/15/09 | FIN 302 | $35,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALSINGULAIR - MERCK FROSSTNEW PRIOR ART IDENTIFIED FOR MERCK'S SINGULAIR U.S. PATENT! Article One congratulates our two winning Advisors! Merck sued Teva for patent infringement to prevent Teva from making a generic version of SINGULAIR, with Merck's U.S. patent expiring in 2012 and $4.3 billion 2008 worldwide sales for SINGULAIR. |
02/20/09 | MRK 473 | $50,000 |
AEKall ARTIOREL |
TECHNOLOGY - SEMICONDUCTORSSEMICONDUCTORS - RAMBUSArticle One received highly relevant prior art submissions for some of the Rambus patents. |
02/20/09 | RMBS 184 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - SEMICONDUCTORSSEMICONDUCTORS - LSIWINNING PRIOR ART FOUND TO INVALIDATE LSI's U.S. PATENT! LSI's U.S. patent asserted in the International Trade Commission against 20 defendants to block imports of semiconductors used in a "wide array of products" as described by LSI is invalid. |
01/29/09 | LSI 335 | $50,000 |
RickyJames Ritwik Haferi |
TECHNOLOGY - SEMICONDUCTORSSEMICONDUCTORS - NATIONAL SEMICONDUCTORBased on the response of the Article One community, the validity of the Study patents is not impacted by the Article One community research. |
01/29/09 | NSM 440 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALBONIVA - ROCHEArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. |
01/29/09 | RHHBY 938 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
HEALTHCARE - PHARMACEUTICALPROTONIX - WYETHArticle One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. |
01/29/09 | WYE 579 | $50,000 |
CLOSED Advisors Earn Profit Sharing POINTS |
TECHNOLOGY - WIRELESS COMMUNICATIONGPS GRAPHICAL INTERFACE - SPT/GARMINWINNING STUDY, PRIOR ART IDENTIFIED FOR GARMIN'S DEFENSE AGAINST SP TECHNOLOGY'S PATENT INFRINGEMENT LITIGATION! Article One is delighted to announce our community's first winning Advisors - RickyJames and Patented - for their success in identifying winning prior art for this Study. RickyJames was first to submit his winning prior art and so earns $35,000.00. Patented was second to submit the winning prior art, earning $15,000.00. RickyJames and Patented also join the ranks of Genius Advisors and are each awarded 500 profit sharing Points. The determination of winners was based on Article One’s analysis, including review and analysis of outside counsel, leading Article One to reach the opinion that the prior art is invalidating because it teaches what is claimed in the subject patent U.S. Patent No. 6,784,873 B1. Article One believes that the claimed inventions would have been obvious to persons of ordinary skill in the relevant art at the time of the inventions. |
01/29/09 | GRMN 873 | $50,000 |
RickyJames Patented |
